Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | CLK1 | P49759 | 2/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 4/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | SGK1 | O00141 | 3/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12829259 | 0.84 | NTRK1 (0.66) | KITDYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL8320542 | 0.84 | DYRK1A (0.59) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1800807 | 0.84 | AXL (0.73) | KITAXLTNIKCDK8NTRK1 | |
| SCHEMBL1487612 | 0.81 | MAPK8 (0.67) | KITDYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL8320227 | 0.81 | KIT (0.67) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8320268 | 0.81 | KIT (0.61) | KITDYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL1053943 | 0.80 | JAK2 (0.58) | KITAXLTNIKCDK8BRD4 | |
| Ammonia Solution, Strong SCHEMBL27890807 | 0.78 | JAK2 (0.57) | KITAXLTNIKCDK8BRD4 | |
| SCHEMBL21241576 | 0.78 | KIT (0.46) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL24023131 | 0.78 | KIT (0.52) | KITCCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| WO-2018134254-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, HNF4A, HGF | KIT 3284/4885CCNT1 2663/4885CCNA2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.